|Day Low/High||100.52 / 101.74|
|52 Wk Low/High||34.53 / 114.20|
Shares of Spark Therapeutics slide amid a second regulatory-related delay of its $4.3 billion deal with Swiss pharmaceuticals group Roche Holdings AG.
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Spark Therapeutics Inc , where a total of 6,624 contracts have traded so far, representing approximately 662,400 underlying shares. That amounts to about 172.6% of ONCE's average daily trading volume over the past month of 383,765 shares.
Roche plans to regroup on its $4.3 billion offer to buy Spark Therapeutics after failing to win enough Spark shareholder votes, or receiving U.S. regulatory approval.
NEW YORK, March 22, 2019 /PRNewswire/ -- AVEO Pharmaceuticals, Inc. (AVEO) Lifshitz & Miller announces investigation into possible securities laws violations in connection with the FDA seeking additional survival data concerning tivozanib echoing concerns...
Roku was hit with a pair of downgrades on Wednesday
NEW YORK, March 11, 2019 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Spark Therapeutics, Inc.
Jim Cramer asks whether there aren't enough good things happening that we can sustain an advance without a China deal.
ETFs could see big inflows again and Sparks stock soars; these are among the important market items today.
The Dow Jones Industrial Average rose modestly Monday after Donald Trump said he will delay increasing tariffs on China-made goods.
If we can advance without China then who the heck knows where we can go with it.
Spark Therapeutics shares more than double Monday after the gene therapy specialist agreed to a $4.3 billion takeover by Switzerland-based Roche Holding, the world's biggest maker of cancer treatments.
Acquisition deals for biotech companies at the start of 2019 are giving the sector a nice boost; here are other names that could be merger candidates.
U.S. stock futures rise after Donald Trump says he will delay increasing tariffs on China-made goods; Swiss drug giant Roche to buy Spark Therapeutics for about $4.8 billion; Warren Buffett wants to make an 'elephant-sized acquisition'; Kraft Heinz reportedly reviewing options for Maxwell House.
StocksGlobal stocks traded higher Monday after President Donald Trump said he would delay the increase of tariffs on China-made goods, set to kick-in on March 1, following "substantial progress" over two weeks of trade talks between Washington and Beijing.
The price is nearly $3 billion over Spark's market cap of $1.95 billion as of Friday's close. Deal is slated to close in the second quarter of 2019.
Predicted price would be nearly $3 billion over Spark's market cap as of Friday's close, but Roche spokesman claims report is 'market rumor.'
Investors in Spark Therapeutics Inc saw new options become available this week, for the February 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ONCE options chain for the new February 15th contracts and identified one put and one call contract of particular interest.
Investors in Spark Therapeutics Inc saw new options become available this week, for the November 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ONCE options chain for the new November 16th contracts and identified one put and one call contract of particular interest.
Follow the experts. These biotech stocks have Wall Street's best analysts getting bullish.
Pfizer Inc. (NYSE:PFE) and Spark Therapeutics (NASDAQ:ONCE) announced today that Pfizer initiated a Phase 3 open-label, multi-center, lead-in study ( NCT03587116) to evaluate the efficacy and safety of current factor IX prophylaxis replacement therapy in...
Investors in Spark Therapeutics Inc saw new options begin trading this week, for the August 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ONCE options chain for the new August 17th contracts and identified one put and one call contract of particular interest.
In recent trading, shares of Spark Therapeutics Inc have crossed above the average analyst 12-month target price of $78.22, changing hands for $78.53/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
U.S. Food and Drug Administration (FDA) grants breakthrough therapy designation to SPK-8011 for hemophilia A
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.